Acute community-acquired pneumonia. A review of clinical trials;Pneumonies aiguës communautaires : analyse critique des essais cliniques

Medecine et Maladies Infectieuses

Volumn 36, Issue 11-12, 2006, Pages 650-666

  Chidiac, C ^a  

^a CROIX ROUSSE HOSPITAL   (France)

Author keywords

Antibiotic treatment; Community acquired pneumonia

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; TELITHROMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE SEVERITY; DRUG CHOICE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LEGIONNAIRE DISEASE; MEDLINE; MICROBIOLOGY; MONOTHERAPY; POPULATION RESEARCH; RISK FACTOR; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 33845192237     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2006.05.009     Document Type: Article

References (57)

1. Anonyme. IVe conféence de consnsus en thérapeutiqueanti-infectieuse de la SPILF : Les infections des voies respiratoires 18 octobre 1991, Lille. ed Mal. Inf. 1992 ; 22, Supplément 2 : 43-6.
2. Mouton Y., Bignolas G., Chidiac C., Decazes J.M., Gehanno P., and et groupe de travail. Recommandations sur la prise en charge de la pathologie infectieuse respiratoire. Med. Mal. Inf. 25 (1995) 1021-1028
3. e conférence de consensus en thérapeutique anti-infectieuse de la Société de pathologie infectieuse de langue française (SPILF). Med Mal Inf 31 (2001) 265-266
4. Afssaps. Antibiothérapie par voie générale en pratique courante : infections respiratoires basses de l'adulte. Med. Mal. Inf. 32 (2002) 125-126
5. Afssaps. Antibiothérapie par voie générale en pratique courante infections respiratoires basses de l'adulte et de l'enfant (actualisation novembre 2005). Antibiothérapie par voie générale en pratique courante au cours des infections respiratoires basses de l'adulte et de l'enfant. Med. Mal. Inf. 2005; 35 : 619-34. http://afssaps.sante.fr/htm/5/rbp/indantib.htm.
6. Beaucaire G., and Beusacrt C. Traitement des pneumonies supposées à germes extracellulaires : analyse critique des essais. Med. Mal. Inf. 22 spécial (1992) 183-193
7. Garré M., Potard M., Hiar I., Tonnelier J.M., and Gentric A. Traitement antibiotique des pneumonies communautaires de l'adulte-apport des nouvelles molécules ; place des traitements de durée abrégée ; données pharmacoéconomiques. Med. Mal. Inf. 31 (2001) 174-180
8. Anaes. Guide d'analyse de la littérature et gradation des recommandations. Janvier 2000 http://www.anaes.fr/anaes/anaesparametrage.nsf/Page?ReadForm&Section=/anaes/Rechercher.nsf/Rechercher?OpenAgent&Fuzzy=c&query=analyse+and+article§rec=all.
9. Committee for Proprietary Medical Products. Note for guidance on statistical principles for clinical trials (1997). European Agency for the Evaluation of Medical Products. http://www.eudra.org/emea.html.
10. Food and Drug Administration. Guidance for industry. Developing antimicrobial drugs. Général considérations for clinical trials (1997). http://www.fda.gov/cder/guidance/index.htm.
11. Food and Drug Administration. Guidance for industry. Community-acquired pneumonia-developing antimicrobial drugs for treatment (1998). http://www.fda.gov/cder/guidance/index.htm.
12. Chow A.W., Hall C.B., Klein J.O., Kammer R.B., Meyer R.D., and Remington J.S. Evaluation of new anti-infective drugs for the treatment of respiratory tract infection. Clin. Infect. Dis. 15 suppl 1 (1992) S62-S68
13. Fine Fine M.J., Auble T.E., Yealy D.M., Hanusa B.H., Weissfeld L.A., Singer D.E., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336 (1997) 243-250
14. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., et al., American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163 7 (2001) 1730-1754
15. Moola S., Hagberg L., Churchyard G.A., Dylewski J.S., Sedani S., and Staley H. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest 116 4 (1999) 974-983
16. Bartoloni A., Strohmeyer M., Corti G., Buonomini M.I., Franchino L., Romanelli G., et al. Multicenter randomized trial comparing MER (1,5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drugs Exp. Clin. Res. 25 6 (1999) 243-252
17. Rovira E., Martinez-Moragon E., Belda A., Gonzalvo F., Ripolles F., and Pascual J.M. Treatment of community-acquired pneumonia in outpatients :randomized study of clarithromycin alone versus clarithromycin and cefuroxime. Respiration (Herrlisheim) 66 (1999) 413-418
18. File Jr. T.M., Schlemmer B., Garau J., Cupo M., and Young C. 049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J. Antimicrob. Chemother. 48 1 (2001) 67-74
19. Sokol Jr. W.N., Sullivan J.G., Acampora M.D., Busman T.A., and Notario G.F. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia. Clin. Ther. 24 4 (2002) 605-615
20. Pullman J., Champlin J., and Vrooman Jr. P.S. Efficacy and tolerability of once-daily oral therapy with télithromycine compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int. J. Clin. Pract. 57 5 (2003) 377-384
21. Rahav G., Fidel J., Gibor Y., and Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int. J. Antimicrob. Agents 24 2 (2004) 181-184
22. Vergis E.N., Indorf A., File Jr. T.M., Phillips J., Bates J., Tan J., et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch. Intern. Med. 8 160 (2000) 1294-1300 (9)
23. Carbon C., Azriza H., Rabie W.J., Salvarezza C.R., Elkharrat D., Rangaraj M., et al. Comparaive study of lévofloxacine and amoxycillin/clavulanic acid in adults with mil-to-moderate community-acquired pneumonia. Clin. Microbiol. Infect. 5 (1999) 724-732
24. Finch R., Schurmann D., Collins O., Kubin R., McGivern J., Bobbaers H., et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother. 46 6 (2002) 1746-1754
25. Garau J., Twynholm M., Garcia-Mendez E., Siquier B., and Rivero A. 557 Clinical Study Group. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J. Antimicrob. Chemother. 52 5 (2003) 826-836
26. File Jr. T.M., Lode H., Kurz H., Kozak R., Xie H., Berkowitz E., and 600 Study Group. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob. Agents Chemother. 48 9 (2004) 3323-3331
27. Bonvehi P., Weber K., Buscan T., Shortridge D., and Notario G. Comparison of clarithromycin and amoxicillin/clavulanic acid for community-acquired pneumonia in an era of drug-resistant Streptococcus pneumoniae. Clin Drug Invest 23 (2003) 491-501
28. Hoeffken G., Meyer H.P., Winter J., Verhoef L., and CAP1 Study Group. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir. Med. 95 7 (2001) 553-564
29. Petitpretz P., Chidiac C., Soriano F., Garau J., Stevenson K., Rouffiac E., and 556. Clinical Study Group. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int. J. Antimicrob. Agents 20 2 (2002) 119-129
30. Torres A., Muir J.F., Corris P., Kubin R., Duprat-Lomon I., Sagnier P.P., et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur. Respir. J. 21 1 (2003) 135-143
31. Vetter N., Cambronero-Hernandez E., Rohlf J., Simon S., Carides A., Oliveria T., et al. Protocol 020 Study Group. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin. Ther. 24 11 (2002) 1770-1785
32. Ortiz-Ruiz G., Caballero-Lopez J., Friedland I.R., Woods G.L., Carides A., and Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety, and tolerability of ertapenem vs ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin. Infect. Dis. 15 34 (2002) 1076-1083 (8)
33. Woods G.L., Isaacs R.D., McCarroll K.A., and Friedland I.R. Ertapenem therapy for community-acquired pneumonia in the elderly. J. Am. Geriatr. Soc. 51 11 (2003) 1526-1532
34. Welte T., Petermann W., Schuermann D., Bauer T.T., Reimnitz P., and the MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clinical Infect. Dis. 41 (2005) 1697-1705
35. Lode H., File Jr. T.M., Mandell L., Ball P., Pypstra R., and Thomas M. 185 Gemifloxacin Study Group. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin. Ther. 24 11 (2002) 1915-1936
36. Leophonte P., File T., and Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir. Med. 98 8 (2004) 708-720
37. Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther. 2002;24(8):1292-308. Erratum in. Clin. Ther. 2003;25(3):1039.
38. Leroy O., Saux P., Bedos J.P., and Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 128 1 (2005) 172-183
39. Fogarty C., Grossman C., Williams J., Haverstock D., and Church D. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect. Med. 16 (1999) 748-763
40. Petitpretz P., Arvis P., Marel M., Moita J., Urueta J., and CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 119 1 (2001) 185-195
41. Katz E., Larsen L.S., Fogarty C.M., Hamed K., Song J., and Choudhri S. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J. Emerg. Med. 27 4 (2004) 395-405
42. Portier H., Brambilla C., Garre M., Paganin F., Poubeau P., and Zuck P. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur. J. Clin. Microbiol. Infect. Dis. 24 6 (2005) 367-376
43. Anzueto A., Niederman M.S., Pearle J., Restrepo M.I., Heyder A., Choudhri S.H., and for the Community-Acquired Pneumonia Recovery in the Elderly Study Group. Community-acquired pneumonia recovery in the elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy vs that of levofloxacin therapy. Clin. Infect. Dis. 42 (2006) 73-81
44. Hagberg L., Torres A., van Rensburg D., Leroy B., Rangaraju M., and Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 30 6 (2002) 378-386
45. Dunbar M.L., Hassman J., and Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin. Ther. 26 1 (2004) 48-62
46. Tellier G., Niederman M.S., Nusrat R., Patel M., and Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J. Antimicrob. Chemother. 54 2 (2004) 515-523
47. Gotfried M.H., Dattani D., Riffer E., Devcich K.J., Busman T.A., Notario G.F., et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin. Ther. 24 5 (2002) 736-751
48. D'Ignazio J., Camere M.A., Lewis D.E., Jorgensen D., and Breen J.D. Novel, single-dose microsphere formulation of azithromycin vs 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrob. Agents Chemother. 49 10 (2005) 4035-4041
49. Drehobl M.A., De Salvo M.C., Lewis D.E., and Breen J.D. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 128 4 (2005) 2230-2237
50. Trémolières F., Mayaud C., Mouton Y., Weber P., Dellatolas F., Caulin E., and groupe d'investigateurs. Essai comparatif de l'efficacité et de la tolérance de la pristinamycine vs amoxicilline dans le traitement des pneumonies aiguës communautaires de l'adulte. Pathol. Biol. 53 (2005) 503-510
51. Dunbar L.M., Wunderick R.G., Habib M.P., Smith L.G., Tennenberg A.M., Khashab M.M., et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new paradigm. Clin. Infect. Dis. 37 (2003) 752-760
52. Plouffe J.F., Breiman R.F., Fields B.S., Herbert M., Inverso J., Knirsch C., et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin. Infect. Dis. 37 (2003) 1475-1480
53. Yu V.L., Greenberg R.N., Zadeikis N., Stout J.E., Khashab M.M., Olson W.H., et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 125 (2004) 2135-2139
54. Blazquez Garrido R.M., Espinosa Parra F.J., Alemany Frances L., Ramos Guevara R.M., Sanchez-Nieto J.M., Segovia Hernandez M., et al. Antimicrobial chemotherapy for legionnaires disease: levofloxacin vs macrolides. Clin. Infect. Dis. 40 (2005) 800-806
55. Carbon C., and Nusrat R. Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila. Eur. J. Clin. Microbiol. Infect. Dis. 23 (2004) 650-652
56. Norrby S.R., Petermann W., Willcox P.A., Vetter N., and Salewski E. A comparative study of lévofloxacine and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand. J. Infect. Dis. 30 (1998) 397-406
57. Piroth L., Martin L., Coulon A., et al. Development of new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob. Agents Chemother. 10 (1999) 2484-2492